| Citation: |
CHEN Hongda, CHEN Wanqing. Evaluation of Cancer Burden Based on Big Data: Applications and Challenges in Cancer Prevention and Treatment[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 506-512. DOI: 10.12290/xhyxzz.2025-0083
|
Cancer has become one of the most significant diseases threatening human life and health. In 2022, there were 19.97 million new cancer cases and 9.74 million cancer-related deaths worldwide, imposing a heavy burden on society. A systematic and comprehensive understanding of the cancer burden is the cornerstone for formulating effective prevention and control strategies. Open-source databases, represented by the GLOBOCAN database and the Global Burden of Disease (GBD) database, provide critical support for obtaining the latest cancer burden data, identifying key areas for prevention and control, guiding screening and early diagnosis and treatment, and evaluating the effectiveness of intervention measures. However, the field of cancer big data also faces challenges, such as insufficient data standardization and inadequate privacy protection mechanisms. In the future, while ensuring patient privacy and security, efforts should be made to further improve data quality, promote data sharing, enhance the equity of cancer prevention and treatment resources, and strengthen international collaboration. These measures will reasonably advance the precision and scientific development of cancer prevention and control strategies, with the aim of reducing the cancer burden and contributing to global health and well-being.
| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834
|
| [2] |
Han B F, Zheng R S, Zeng H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006
|
| [3] |
Zeng H M, Zheng R S, Sun K X, et al. Cancer survival statistics in China 2019—2021: a multicenter, population-based study[J]. J Natl Cancer Cent, 2024, 4(3): 203-213. DOI: 10.1016/j.jncc.2024.06.005
|
| [4] |
Siegel R L, Kratzer T B, Giaquinto A N, et al. Cancer statistics, 2025[J]. CA Cancer J Clin, 2025, 75(1): 10-45. DOI: 10.3322/caac.21871
|
| [5] |
郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035
Zheng R S, Chen R, Han B F, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035
|
| [6] |
中国疾病预防控制中心慢性非传染性疾病预防控制中心, 国家卫生健康委统计信息中心. 中国死因监测数据集-2021[M]. 北京: 中国科学技术出版社, 2022: 1-10.
Chronic Non-Communicable Disease Prevention and Control Center of China Center for Disease Control and Prevention, National Health Commission Statistical Information Center. Chinese cause of death surveillance dataset 2021[M]. Beijing: China Science and Technology Press, 2022: 1-10.
|
| [7] |
International Agency for Research on Cancer. Global cancer observatory[EB/OL]. [2025-02-04]. https://gco.iarc.fr/.
|
| [8] |
Institute for Health Metrics and Evaluation. Global burden of disease (GBD)[EB/OL]. [2025-02-04]. https://www.healthdata.org/research-analysis/gbd.
|
| [9] |
GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990—2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2133-2161. DOI: 10.1016/S0140-6736(24)00757-8
|
| [10] |
GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990—2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403(10440): 2162-2203. DOI: 10.1016/S0140-6736(24)00933-4
|
| [11] |
Wang S M, Zheng R S, Li J Y, et al. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN[J]. Lancet Gastroenterol Hepatol, 2024, 9(3): 229-237. DOI: 10.1016/S2468-1253(23)00366-7
|
| [12] |
Zhou Y Y, Song K, Chen Y Q, et al. Burden of six major types of digestive system cancers globally and in China[J]. Chin Med J (Engl), 2024, 137(16): 1957-1964. DOI: 10.1097/CM9.0000000000003225
|
| [13] |
Seum T, Hoffmeister M, Brenner H. Risk-adapted starting ages of colorectal cancer screening for people with diabetes or metabolic syndrome[J]. Aliment Pharmacol Ther, 2025, 61(4): 675-681. DOI: 10.1111/apt.18435
|
| [14] |
Meng Y, Tan Z B, Zhen J H, et al. Global, regional, and national burden of early-onset colorectal cancer from 1990 to 2021: a systematic analysis based on the global burden of disease study 2021[J]. BMC Med, 2025, 23(1): 34. DOI: 10.1186/s12916-025-03867-9
|
| [15] |
Wu Y J, He S Y, Cao M D, et al. Comparative analysis of cancer statistics in China and the United States in 2024[J]. Chin Med J (Engl), 2024, 137(24): 3093-3100. DOI: 10.1097/CM9.0000000000003442
|
| [16] |
Placido D, Yuan B, Hjaltelin J X, et al. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories[J]. Nat Med, 2023, 29(5): 1113-1122. DOI: 10.1038/s41591-023-02332-5
|
| [17] |
Guevara M, Chen S, Thomas S, et al. Large language models to identify social determinants of health in electronic health records[J]. NPJ Digit Med, 2024, 7(1): 6. DOI: 10.1038/s41746-023-00970-0
|
| [18] |
London School of Hygiene & Tropical Medicine. CONCORD programme[EB/OL]. [2025-02-06]. https://csg.lshtm.ac.uk/research/themes/concord-programme/.
|
| [19] |
International Agency for Research on Cancer. CanScreen5[EB/OL]. [2025-02-06]. https://canscreen5.iarc.fr/.
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: